AMICUS THERAPEUTICS, INC.

Amicus Therapeutics Inc. is a biotechnology company dedicated to discovering, developing, and commercializing therapies for rare and orphan diseases. It focuses on addressing unmet medical needs in genetic disorders through proprietary technology platforms, with a portfolio centered on treatments for conditions such as Fabry disease and Pompe disease. Key products include Galafold, an oral precision medicine for Fabry patients with amenable genetic variants, and Pombiliti combined with Opfolda as a treatment paradigm for late-onset Pompe disease. The company also advances a rare disease gene therapy portfolio. Operating as a single segment, Amicus Therapeutics Inc. emphasizes patient-centric innovation to deliver high-quality medicines that improve outcomes for individuals living with these devastating conditions. Founded in 2002 and headquartered in the United States, it plays a vital role in the biotechnology sector by targeting underserved rare disease markets worldwide.